ASEP Webinar Overview (held on March 3)Just hopped off the Investor Information Webinar that was quite interesting & informative - they will be providing attendees with a recoding link within 24 hours which I will share once I receive it.
The ASEP team covered the investor presentation and gave a general overview of the company which is positioned to capitalize on a multibillion dollar opportunity.
Diagnostic Approach Highlights:
- In the final stages of the assay for diagnostic approach
- Significant results so far with a 92% accuracy rate (vs 50% accuracy rate for current method)
- Approval expected in 2022
- In the early stages of an additional method for a different type of sepsis
Therapeutic Approach Highlights:
- Potent activity against all major clinically relevant bacteria growing as antibiotic resistant biofilms
- Initial clinical opportunity for peptide technology is chronic rhinosinusitis (CRS) which has a cost of 30,000/year with the current treatment method which has shown poor efficacy (gives an idea of the market $ASEP is operating in)
- Validation studies have shown ASEP's peptide technology is the first therapy ever that has an antibacterial and anti-inflammatory response
Additional Highlights:
- OTC market listing with DTC eligibility expected in a few weeks under $SEPSF (NASDAQ listing expected 4-6 months after OTC)
- Orphan drug designation allows movement through clinical trials in 4-5 years rather than 8-10 years
- Opportunity for near-term revenue with regulatory approval for diagnostic approach expected by the end of the year
- ASEP's capital runway is sufficient for 12-18 months
- Working on FDA 510(k) approval for Sepset & is preparing for Health Canada and EU approval following US approval
- In discussions with the largest companies in the market but can't disclose at the time
- Management team and employees with stock option plans have a stake in the company
- Planning to have a strong presence at conferences (Ex. BIO) and have future webinars and podcasts planned to attract additional investors
2022 Catalysts:
- Diagnostic process
- FDA 501(k) filing
- Partnership opportunities
- Large grant funding opportunity to be announced in the near future
Overall, it was a really informative webinar and I'd definitely recommend checking out the recording once its available, as well as attending any future webinars.
https://asepmedical.com/investors/